AR070513A1 - Uso de abridores de canales de potasio kcnq para reducir los sintomas o tratar desordenes o afecciones en las cuales se encuentra anulado el sis-tema dopaminergico como por ejemplo esquizofrenia y trastorno depresivo mayor - Google Patents

Uso de abridores de canales de potasio kcnq para reducir los sintomas o tratar desordenes o afecciones en las cuales se encuentra anulado el sis-tema dopaminergico como por ejemplo esquizofrenia y trastorno depresivo mayor

Info

Publication number
AR070513A1
AR070513A1 ARP080103329A ARP080103329A AR070513A1 AR 070513 A1 AR070513 A1 AR 070513A1 AR P080103329 A ARP080103329 A AR P080103329A AR P080103329 A ARP080103329 A AR P080103329A AR 070513 A1 AR070513 A1 AR 070513A1
Authority
AR
Argentina
Prior art keywords
alkyl
cycloalkyl
ilo
halo
hydroxy
Prior art date
Application number
ARP080103329A
Other languages
English (en)
Spanish (es)
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39810209&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR070513(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of AR070513A1 publication Critical patent/AR070513A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Reproductive Health (AREA)
  • Anesthesiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP080103329A 2007-08-01 2008-07-31 Uso de abridores de canales de potasio kcnq para reducir los sintomas o tratar desordenes o afecciones en las cuales se encuentra anulado el sis-tema dopaminergico como por ejemplo esquizofrenia y trastorno depresivo mayor AR070513A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200701110 2007-08-01

Publications (1)

Publication Number Publication Date
AR070513A1 true AR070513A1 (es) 2010-04-14

Family

ID=39810209

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080103329A AR070513A1 (es) 2007-08-01 2008-07-31 Uso de abridores de canales de potasio kcnq para reducir los sintomas o tratar desordenes o afecciones en las cuales se encuentra anulado el sis-tema dopaminergico como por ejemplo esquizofrenia y trastorno depresivo mayor

Country Status (17)

Country Link
US (1) US20100256145A1 (enExample)
EP (1) EP2185149A1 (enExample)
JP (1) JP2011513196A (enExample)
KR (1) KR20100050502A (enExample)
CN (1) CN101790374A (enExample)
AR (1) AR070513A1 (enExample)
AU (1) AU2008281112A1 (enExample)
BR (1) BRPI0814180A2 (enExample)
CA (1) CA2694887A1 (enExample)
CL (1) CL2008002273A1 (enExample)
EA (1) EA201070189A1 (enExample)
MX (1) MX2010001171A (enExample)
NZ (1) NZ582942A (enExample)
TW (1) TW200920350A (enExample)
UA (1) UA97847C2 (enExample)
WO (1) WO2009015667A1 (enExample)
ZA (1) ZA201000129B (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0700353A2 (en) * 2007-05-18 2008-12-29 Richter Gedeon Nyrt Metabolites of (thio)carbamoyl-cyclohexane derivatives
US7875610B2 (en) * 2007-12-03 2011-01-25 Richter Gedeon Nyrt. Pyrimidinyl-piperazines useful as D3/D2 receptor ligands
JP4409630B2 (ja) * 2008-02-21 2010-02-03 田辺三菱製薬株式会社 経口投与用固形製剤
ES2532636T3 (es) 2008-07-16 2015-03-30 Richter Gedeon Nyrt. Formulaciones farmacéuticas que contienen ligandos de receptores de dopamina
HU230067B1 (hu) 2008-12-17 2015-06-29 Richter Gedeon Nyrt Új piperazin só és eljárás előállítására
HUP0800765A2 (en) 2008-12-18 2010-11-29 Richter Gedeon Nyrt A new process for the preparation of piperazine derivatives and their hydrochloric salts
HUP0800766A2 (en) 2008-12-18 2010-11-29 Richter Gedeon Vegyeszet Process for the preparation of piperazine derivatives
WO2010105189A1 (en) * 2009-03-12 2010-09-16 The Johns Hopkins University Method for identifying compounds that attenuate the function or reduce abundance of a voltage-gated potassium channel and are associated with maintenance of cognitive function in old age
WO2010105960A1 (en) 2009-03-17 2010-09-23 Neurosearch A/S Substituted pyridine derivatives and their medical use
DE102009013612A1 (de) * 2009-03-17 2010-09-23 Ratiopharm Gmbh Retigabin-Tabletten, bevorzugt mit modifizierter Freisetzung
TW201041857A (en) * 2009-05-11 2010-12-01 Lundbeck & Co As H Stable forms of N-(2,6-dimethyl-4-morpholin-4-yl-phenyl)-3,3-dimethyl-butyramide
CN102448495A (zh) * 2009-05-29 2012-05-09 安斯泰来制药株式会社 用于预防和/或治疗注意缺陷/多动障碍的新型医药组合物
WO2011133661A2 (en) 2010-04-21 2011-10-27 Research Development Foundation Methods and compositions related to dopaminergic neuronal cells
CA2804165C (en) 2010-07-08 2015-02-24 Pfizer Inc. Piperidinyl pyrimidine amides as kv7 potassium channel openers
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
US9321750B2 (en) * 2012-04-20 2016-04-26 Innov17 Llc ROR modulators and their uses
CN103508960B (zh) * 2012-06-29 2017-12-12 江苏先声药业有限公司 苯并杂环衍生物
CN103508943B (zh) * 2012-06-29 2017-06-09 江苏先声药业有限公司 作为钾通道调节剂的化合物
CN103012381B (zh) * 2013-01-10 2015-01-07 山东大学 苯基呋喃类化合物、其制备方法及在制备抗心律失常药物中的应用
WO2015084842A1 (en) * 2013-12-02 2015-06-11 Chemocentryx, Inc. Ccr6 compounds
SG11201703284XA (en) * 2014-10-24 2017-06-29 Ono Pharmaceutical Co Kcnq2-5 channel activator
US10526280B2 (en) 2014-11-13 2020-01-07 University of Pittsburgh—of the Commonwealth System of Higher Education (2-amino-4-(arylamino)phenyl carbamates
JP2019518754A (ja) * 2016-06-10 2019-07-04 サイフルーア ライフ サイエンシズ インコーポレイテッド フッ素化２−アミノ−４−（置換アミノ）フェニルカルバメート誘導体
CA2968836C (en) 2016-06-13 2025-09-02 Gilead Sciences, Inc. FXR MODULATING COMPOUNDS (NR1H4)
JP6678779B2 (ja) 2016-06-13 2020-04-08 ギリアード サイエンシーズ， インコーポレイテッド Ｆｘｒ（ｎｒ１ｈ４）調節化合物
US11274087B2 (en) 2016-07-08 2022-03-15 Richter Gedeon Nyrt. Industrial process for the preparation of cariprazine
EP3366683A1 (en) * 2017-02-28 2018-08-29 Acousia Therapeutics GmbH Cyclic amides, acteamides and ureas useful as potassium channel openers
KR20240091322A (ko) 2017-03-28 2024-06-21 길리애드 사이언시즈, 인코포레이티드 간 질환을 치료하기 위한 치료 조합물
WO2019161877A1 (en) 2018-02-20 2019-08-29 H. Lundbeck A/S Alcohol derivatives as kv7 potassium channel openers
US10590067B2 (en) 2018-02-20 2020-03-17 H. Lundbeck A/S Alcohol derivatives of carboxamides as Kv7 potassium channel openers
TWI788325B (zh) * 2018-02-21 2023-01-01 丹麥商Ｈ 朗德貝克公司 作為Ｋｖ７鉀通道開放劑的醇衍生物
WO2019203951A1 (en) * 2018-04-20 2019-10-24 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Selective potassium channel agonists
CN110511220B (zh) * 2018-05-22 2022-04-01 上海挚盟医药科技有限公司 作为钾通道调节剂的对二氨基苯衍生物、其制备方法及其在医药上的应用
CN108707087B (zh) 2018-06-29 2020-10-16 河北医科大学 一种4-(对三氟甲基苄基)-3-氟-1,2,4三苯胺衍生物及其药物组合物与用途
CN108863893A (zh) * 2018-07-09 2018-11-23 湖南博隽生物医药有限公司 二氢吲哚类衍生物及其在药物中的应用
PE20211907A1 (es) 2019-01-15 2021-09-28 Gilead Sciences Inc Compuestos moduladores de fxr (nr1h4)
CA3233305A1 (en) 2019-02-19 2020-08-27 Gilead Sciences, Inc. Solid forms of fxr agonists
US11547707B2 (en) 2019-04-10 2023-01-10 Richter Gedeon Nyrt. Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
AR119521A1 (es) 2019-08-02 2021-12-22 H Lundbeck As DERIVADOS DE ALCOHOL COMO ABRIDORES DEL CANAL DE POTASIO Kv7
CN119490430A (zh) 2019-08-02 2025-02-21 H.隆德贝克有限公司 用于在癫痫或癫痫发作中使用的作为Kv7钾通道开放剂的醇衍生物
CA3148719A1 (en) 2019-08-02 2021-02-11 H. Lundbeck A/S Alcohol derivatives as kv7 potassium channel openers
TWI886158B (zh) 2019-10-10 2025-06-11 加拿大商再諾製藥公司 選擇性鉀通道調節劑之固態晶型
BR112022008580A2 (pt) 2019-11-08 2022-08-09 Xenon Pharmaceuticals Inc Métodos para tratar transtornos depressivos
KR102643653B1 (ko) * 2020-11-13 2024-03-06 기초과학연구원 신규한 아미노방향족 화합물 또는 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 포함하는 신경퇴행성 질환의 예방 또는 치료용 약학적 조성물
EP4291189A1 (en) 2021-02-09 2023-12-20 Xenon Pharmaceuticals Inc. Voltage-gated potassium channel opener for use in treating anhedonia
CN116535353A (zh) * 2022-01-25 2023-08-04 上海挚盟医药科技有限公司 作为钾通道调节剂的酰胺类化合物及其制备和应用
WO2024099269A1 (zh) * 2022-11-11 2024-05-16 华东师范大学 芳基酰胺化合物、包含其的药物组合物及其用途
TW202521516A (zh) * 2023-08-17 2025-06-01 加拿大商再諾製藥公司 氮雜環庚烷及吡咯啶化合物及其用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN172468B (enExample) * 1990-07-14 1993-08-14 Asta Medica Ag
US6610324B2 (en) * 1999-04-07 2003-08-26 The Mclean Hospital Corporation Flupirtine in the treatment of fibromyalgia and related conditions
GB9915414D0 (en) * 1999-07-01 1999-09-01 Glaxo Group Ltd Medical use
DE60037321D1 (de) * 1999-08-04 2008-01-17 Icagen Inc Benzanilide als öffner des kaliumkanals
US6495550B2 (en) * 1999-08-04 2002-12-17 Icagen, Inc. Pyridine-substituted benzanilides as potassium ion channel openers
EP1441722A2 (en) * 2001-02-20 2004-08-04 Bristol-Myers Squibb Company Modulators of kcnq potassium channels and use thereof in treating migraine and mechanistically related diseases
US6469042B1 (en) * 2001-02-20 2002-10-22 Bristol-Myers Squibb Company Fluoro oxindole derivatives as modulators if KCNQ potassium channels
EP1392644A1 (en) * 2001-05-31 2004-03-03 Bristol-Myers Squibb Company Cinnamide derivatives as kcnq potassium channel modulators
WO2004047744A2 (en) * 2002-11-22 2004-06-10 Bristol-Myers Squibb Company 3-heterocyclic benzylamide derivatives as potassium channel openers
US6933308B2 (en) * 2002-12-20 2005-08-23 Bristol-Myers Squibb Company Aminoalkyl thiazole derivatives as KCNQ modulators
DK1578740T3 (da) * 2002-12-27 2007-07-30 Lundbeck & Co As H 1,2,4-triaminobenzenderivater, der er egnede til behandling af lidelser i centralnervesystemet
EP1603858A2 (en) * 2003-03-11 2005-12-14 NeuroSearch A/S Kcnq channel modulating compounds and their pharmaceutical use
AU2004220424B2 (en) * 2003-03-14 2009-01-22 H. Lundbeck A/S Substituted aniline derivatives
CA2519582A1 (en) * 2003-03-21 2004-09-30 H. Lundbeck A/S Substituted p-diaminobenzene derivatives
JP2006524641A (ja) * 2003-04-25 2006-11-02 ハー・ルンドベック・アクチエゼルスカベット 置換されたインドリンおよびインドール誘導体
TWI357901B (en) * 2004-03-12 2012-02-11 Lundbeck & Co As H Substituted morpholine and thiomorpholine derivati
UA89503C2 (uk) * 2004-09-13 2010-02-10 Х. Луннбек А/С Заміщені похідні аніліну
JP5237643B2 (ja) * 2005-03-03 2013-07-17 ハー・ルンドベック・アクチエゼルスカベット 置換されたピリジン誘導体
AU2006322461A1 (en) * 2005-09-09 2007-06-14 H. Lundbeck A/S Pyrimidine derivatives and their use as KCNQ potassium channels openers
TWI453013B (zh) * 2006-02-07 2014-09-21 Lundbeck & Co As H N-(2,4-二甲基-6-嗎啉-4-基-吡啶-3-基〉3,3-二甲基-丁醯胺之用途以及包含該化合物之醫藥品
EP2012769A1 (en) * 2006-05-02 2009-01-14 Rundfeldt, Chris Potassium channel activators for the prevention and treatment of dystonia and dystonia-like symptoms

Also Published As

Publication number Publication date
AU2008281112A1 (en) 2009-02-05
WO2009015667A1 (en) 2009-02-05
US20100256145A1 (en) 2010-10-07
EA201070189A1 (ru) 2010-08-30
UA97847C2 (ru) 2012-03-26
BRPI0814180A2 (pt) 2015-01-27
CN101790374A (zh) 2010-07-28
EP2185149A1 (en) 2010-05-19
TW200920350A (en) 2009-05-16
ZA201000129B (en) 2011-04-28
CA2694887A1 (en) 2009-02-05
KR20100050502A (ko) 2010-05-13
JP2011513196A (ja) 2011-04-28
CL2008002273A1 (es) 2009-07-17
MX2010001171A (es) 2010-03-01
NZ582942A (en) 2011-09-30

Similar Documents

Publication Publication Date Title
AR070513A1 (es) Uso de abridores de canales de potasio kcnq para reducir los sintomas o tratar desordenes o afecciones en las cuales se encuentra anulado el sis-tema dopaminergico como por ejemplo esquizofrenia y trastorno depresivo mayor
AR065015A1 (es) Derivados de antranilamida, composiciones farmaceuticas que los contienen, y usos para el tratamiento del cancer
EA202090658A1 (ru) Ингибиторы кэп-зависимой эндонуклеазы
PE20212247A1 (es) Compuestos de 3-((3-aminofenil)amino)piperidina-2,6-diona sustituida, composiciones de estos y metodos de tratamiento con estos
AR072227A1 (es) Derivados de triazinona sustituidos
AR077507A1 (es) Derivados de naftiridina-1-ona y composiciones farmaceuticas que los comprenden como inhibidores de cinasa syk
AR066460A2 (es) Compuestos derivados de fenil-piperazina, fenil-piperidina y fenil-tetrahidropiridina como inhibidores de la reabsorcion de la serotonina, una composicion farmaceutica y utilizacion de los mismos para la preparacion de medicamentos
AR062680A1 (es) Sintesis de 2-(piridin-2-ilamino) pirido [2,3-d] pirimidin-7-onas
MX2019004578A (es) Oxisteroles y metodos de uso de los mismos.
AR085960A1 (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
CO6251251A2 (es) Derivados de pirazinona y su uso en el tratamiento de enfermedades pulmonares
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
PE20220948A1 (es) Nuevos derivados piperidinilo sustituidos con (hetero) arilo, un proceso para su preparacion y composiciones farmaceuticas que los contienen
PE20201165A1 (es) Analogos de piridazina 1,4-disustituida y metodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
AR079327A1 (es) Derivados de 2-amino-5,5-difluor -5,6-dihidro-4h-(1,3) oxazin-4-il) fenil)-amida
CL2014003181A1 (es) Compuestos derivados de benzamidas n- sustituidas o piridinamidas n-sustituidas; composicion farmaceutica que los comprende; metodo de tratamiento; y su uso para el tratamiento de enfermedades o trastornos seleccionados de dolor, depresion y enfermedades cardiovasculares, respiratorias o psiquiatricas o combinaciones de estas.
DOP2013000046A (es) Agente de control de plagas
AR075894A1 (es) Derivados oxidados de triazolilpurinas utiles como ligandos de receptor de adenosina a2a y su uso como medicamentos.
AR082889A1 (es) Compuestos y composiciones para la inhibicion de nampt
AR115015A1 (es) Derivados de azaespiro piperazina
PE20142081A1 (es) Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodo de uso de los mismos
MX2016016528A (es) Inhibidores de fosfatidilinositol 3-quinasa.
NZ726638A (en) Phosphatidylinositol 3-kinase inhibitors
AR068466A1 (es) Cianoisoquinolina
BR112016011016A8 (pt) derivados de fenoxietila de amina cíclica, seus usos, e composição farmacêutica.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal